

PROVECTUS BIOPHARMACEUTICALS, INC.  
Form 8-K  
January 24, 2014

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 24, 2014

PROVECTUS BIOPHARMACEUTICALS, INC.  
(Exact name of registrant as specified in charter)

Delaware  
(State or other jurisdiction  
of incorporation)

0-9410  
(Commission  
File Number)

90-0031917  
(IRS Employer  
Identification No.)

7327 Oak Ridge Hwy., Knoxville, Tennessee  
37931  
(Address of Principal Executive Offices)

(866) 594-5999  
(Registrant's Telephone Number, Including Area  
Code)

(Former Name or Former Address, If Changed  
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item Regulation FD Disclosure.

7.01.

On January 24, 2014, Provectus Biopharmaceuticals, Inc. (the “Company”) issued the press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and that is incorporated by reference into this Item, announcing that the Company received the official minutes from the Type C meeting held with the Food and Drug Administration's Division of Oncology Products 2 on December 16, 2013 relating to the Company's oncology drug, PV-10.

Item Financial Statements and Exhibits.  
9.01.

(d) Exhibits.

See Exhibit Index immediately following signature page.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 24, 2014

PROVECTUS BIOPHARMACEUTICALS, INC.

By: /s/ Peter R.  
Culpepper  
Peter R.  
Culpepper  
Chief Financial  
Officer and Chief  
Operating  
Officer

---

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release dated January 24, 2014